| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Jun―29 |
Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change |
Shahd Nofal, Osama Al-said, Khaled Alnimer, Jood Mudar Sarah, Tala Abu Alam, Omar Ali, Dua Abuquteish |
| 2 |
[GO] |
2026―May―07 |
Exploring the long-term hydroxychloroquine’s effects on COVID-19 outcomes in patients with autoimmune diseases: a systematic review and meta-analysis |
Heba M. Amal, Amr Maher Galal Mohamed, Mona Osman Abdel-Halim, Mohamed Said Hassan, Omayma Anwar Khorshid, Walla’a A. Osman |
| 3 |
[GO] |
2026―Apr―07 |
Trends in ADR reporting’ and the missing context: COVID-19, LMICs, and sociodemographic blind spots |
Talha Ali, Muhammad Salman, Mateen Khan |
| 4 |
[GO] |
2025―Feb―13 |
Evaluating the safety and efficacy of nirmatrelvir-ritonavir therapy in pregnant women with COVID-19: a systematic review and meta-analysis |
Omar Hassan, Aya Abdulkarim Elbhairy, Aya Magdy Siam, Tasneem Abdelwahab, Albraa Ashraf Hamad, Omar Ehab Mahmoud, Omnia Azmy Nabeh |
| 5 |
[GO] |
2025―Jan―10 |
Features and results availability of non-commercial Spanish COVID-19 trials: a systematic review of clinical trial registers and corresponding literature |
Rafael Dal-Ré, Elena García-Méndez, Ignacio Mahillo-Fernández |
| 6 |
[GO] |
2024―Aug―23 |
Correction to: Use of antibiotics in the early COVID-19 pandemic in Poland, the Netherlands and Spain, from erraticism to (more) logic |
Aleksandra Opalska, Helga Gardarsdottir, Marcel Kwa, Jadwiga Wójkowska-Mach, Monica Sabate, Maria Elena Ballarin, Mark de Groot, Hubert Leufkens |
| 7 |
[GO] |
2024―Jul―17 |
Use of antibiotics in the early COVID-19 pandemic in Poland, the Netherlands and Spain, from erraticism to (more) logic |
Aleksandra Opalska, Helga Gardarsdottir, Marcel Kwa, Jadwiga Wójkowska-Mach, Monica Sabate, Maria Elena Ballarin, Mark de Groot, Hubert Leufkens |
| 8 |
[GO] |
2024―Jun―27 |
Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review |
Yun Li, Xianlin Li, Xiaojun Zheng |
| 9 |
[GO] |
2024―Jun―24 |
Use of drugs for hypertension or heart failure and the risk of death in COVID-19: association with loop-diuretics |
Johan Fastbom, Gudrun Jonasdottir Bergman, Johanna Holm, Håkan Hanberger, Kristoffer Strålin, Sten Walther, Joakim Alfredsson, Maria State, Natalia Borg, Anastasia Nyman Iliadou |
| 10 |
[GO] |
2024―Feb―12 |
COVID-19 and pregnancy: A European study on pre- and post-infection medication use |
Eimir Hurley, Benjamin P. Geisler, Angela Lupattelli, Beatriz Poblador-Plou, Régis Lassalle, Jérémy Jové, Marie-Agnes Bernard, Dunia Sakr, Gabriel Sanfélix-Gimeno, Francisco Sánchez-Saez, Clara L. Rodríguez-Bernal, Mònica Sabaté, Elena Ballarín, Cristina Aguilera, Sue Jordan, Daniel Thayer, Ian Farr, Saira Ahmed, Claudia Bartolini, Giorgio Limoncella, Olga Paoletti, Rosa Gini, Luigi A. Maglanoc, Elena Dudukina, Vera Ehrenstein, Ema Alsina, Tiago A. Vaz, Judit Riera-Arnau, Miriam C. J. M. Sturkenboom, Hedvig M. E. Nordeng |
| 11 |
[GO] |
2024―Jan―12 |
Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database |
Seohyun Kim, Sungho Bea, Seung-Ah Choe, Nam-Kyong Choi, Ju-Young Shin |
| 12 |
[GO] |
2023―Jul―01 |
Might chronic spontaneous urticaria develop after SARS-CoV-2 vaccinations? |
Öner Özdemir |
| 13 |
[GO] |
2023―Jun―09 |
How to make the best of NLRP3 inhibitors in patients with COVID-19? |
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan |
| 14 |
[GO] |
2023―May―26 |
Seronegative acute encephalitis following COVID-19 vaccines: a case series of an overlooked diagnosis with literature review |
Khadija Mansour, Zohra Chadli, Ichrak Ghachem, Nadia Ben Fredj, Haifa Ben Romdhane, Najah Ben Fadhel, Naceurs Boughatas, Karim Aouam, Amel Chaabane, Samia Younes |
| 15 |
[GO] |
2023―May―22 |
Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience |
Emilio Attena, Alfredo Caturano, Anna Annunziata, Alberto Enrico Maraolo, Annunziata De Rosa, Francesco Maria Fusco, Geza Halasz, Valeria Dall’Ospedale, Maddalena Conte, Valentina Parisi, Raffaele Galiero, Ferdinando Carlo Sasso, Giuseppe Fiorentino, Vincenzo Russo |
| 16 |
[GO] |
2023―Apr―20 |
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies |
Elisa Souza Vaz, Sandra Valeria Vassiliades, Jeanine Giarolla, Michelle Carneiro Polli, Roberto Parise-Filho |
| 17 |
[GO] |
2023―Mar―24 |
Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis |
Greta Santi Laurini, Nicola Montanaro, Domenico Motola |
| 18 |
[GO] |
2023―Mar―24 |
Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study |
Vladimir Trkulja, Ivan Kodvanj |
| 19 |
[GO] |
2022―Dec―23 |
Why we should not recommend or offer fluvoxamine to COVID-19 patients? |
Vladimir Trkulja |
| 20 |
[GO] |
2022―Dec―17 |
Imprecision in adverse event reports following immunization against HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and government policy |
Yasuko Inokuma, Robert Kneller |
| 21 |
[GO] |
2022―Oct―18 |
Case series of chronic spontaneous urticaria following COVID-19 vaccines: an unusual skin manifestation |
Nadia Ben-Fredj, Ferdaous Chahed, Najah Ben-Fadhel, Khadija Mansour, Haifa Ben-Romdhane, Randa Said El Mabrouk, Zohra Chadli, Donia Ghedira, Hichem Belhadjali, Amel Chaabane, Karim Aouam |
| 22 |
[GO] |
2022―Sep―14 |
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic |
Selena Russo, Marco Bani, Marco Terraneo, Valeria Quaglia, Giampaolo Nuvolati, Rebecca Cavaliere, Serena Capici, Marina Elena Cazzaniga, Maria Grazia Strepparava |
| 23 |
[GO] |
2022―Sep―06 |
Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials |
Paulo Ricardo Martins-Filho, Edmundo Marques do Nascimento-Júnior, José Antônio Barreto-Alves, Ricardo Fakhouri, Lis Campos Ferreira |
| 24 |
[GO] |
2022―Aug―09 |
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use |
Vitória Segabinazzi Foletto, Taciéli Fagundes da Rosa, Marissa Bolson Serafin, Rosmari Hörner |
| 25 |
[GO] |
2022―Aug―05 |
COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed |
Nadir Yalcin, Karel Allegaert |
| 26 |
[GO] |
2022―Jun―22 |
Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis |
Shaodi Ma, Wanying Su, Chenyu Sun, Scott Lowe, Zhen Zhou, Haixia Liu, Guangbo Qu, Weihang Xia, Peng Xie, Birong Wu, Juan Gao, Linya Feng, Yehuan Sun |
| 27 |
[GO] |
2022―May―17 |
Correction to: Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis |
Hong-Bae Kim, Jung-Ha Kim, Bethany J. Wolf |
| 28 |
[GO] |
2022―May―16 |
Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19 |
Dan-Na Wu, Li-Rong Jiao, Guo-Fu Li, Guo Yu |
| 29 |
[GO] |
2022―May―16 |
Authors’ reply to the letter to editor “Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis” |
Hong-Bae Kim, Jung-Ha Kim, Bethany J. Wolf |
| 30 |
[GO] |
2022―Mar―03 |
Correction to: Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis |
Massimo Tempestilli, Giulia Valeria Stazi, Gaetano Maffongelli, Maria Cristina Marini, Tommaso Ascoli Bartoli, Giuseppe Ippolito, Emanuele Nicastri, Luisa Marchioni, Chiara Agrati |
| 31 |
[GO] |
2022―Jan―28 |
Safety profile of COVID-19 drugs in a real clinical setting |
Mei Nee Chiu, Maitry Bhardwaj, Sangeeta Pilkhwal Sah |
| 32 |
[GO] |
2021―Nov―27 |
Placebo control group in COVID-19 vaccine trials: context and timing matters |
Rafael Dal-Ré |
| 33 |
[GO] |
2021―Nov―24 |
Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis |
Hong-Bae Kim, Jung-Ha Kim, Bethany J. Wolf |
| 34 |
[GO] |
2021―Aug―30 |
Restrictions on the use of placebo in new COVID-19 vaccine trials |
Maurizio Bonati |
| 35 |
[GO] |
2021―Aug―24 |
Correction to: Calling for an exponential escalation scheme in vaccine development for COVID-19 |
Martin Wehling |
| 36 |
[GO] |
2021―Aug―07 |
Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal |
Beatrice Bouhanick, François Montastruc, Samuel Tessier, Clara Brusq, Vanina Bongard, Jean-Michel Senard, Jean-Louis Montastruc, Fabrice Herin |
| 37 |
[GO] |
2021―May―12 |
Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis |
Massimo Tempestilli, Giulia Valeria Stazi, Gaetano Maffongelli, Maria Cristina Marini, Tommaso Ascoli Bartoli, Giuseppe Ippolito, Emanuele Nicastri, Luisa Marchioni, Chiara Agrati |
| 38 |
[GO] |
2021―Apr―25 |
Correction to: Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19 |
Suzy Huijghebaert, Levi Hoste, Guido Vanham |
| 39 |
[GO] |
2021―Mar―27 |
Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19 |
Huijghebaert Suzy, Hoste Levi, Vanham Guido |
| 40 |
[GO] |
2021―Mar―17 |
Correction to: Iron chelation may harm patients with COVID-19 |
Michael D. Garrick, Andrew J. Ghio |
| 41 |
[GO] |
2021―Mar―04 |
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19 |
Nils von Hentig |
| 42 |
[GO] |
2021―Feb―02 |
The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials |
Chia Siang Kow, Syed Shahzad Hasan |
| 43 |
[GO] |
2021―Jan―06 |
Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing |
Vladimir Trkulja |
| 44 |
[GO] |
2021―Jan―03 |
ACE inhibitor-related angioedema in a COVID-19 patient-a plausible contribution of the viral infection? |
Michał Kuzemczak, Charalampos Kavvouras, Mohammad Alkhalil, Mark Osten |
| 45 |
[GO] |
2020―Nov―26 |
Reply to the letter to the Editor “Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts” |
Nicolas Simon, Jean Claude Alvarez |
| 46 |
[GO] |
2020―Nov―25 |
Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts |
Dario Cattaneo, Mario Corbellino, Cristina Gervasoni |
| 47 |
[GO] |
2020―Nov―13 |
Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients |
Xueting Yao, Xiaoyu Yan, Xiaohan Wang, Ting Cai, Shun Zhang, Cheng Cui, Xiaoxu Wang, Zhe Hou, Qi Liu, Haiyan Li, Jing Lin, Zi Xiong, Dongyang Liu |
| 48 |
[GO] |
2020―Oct―13 |
Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients |
Jean Claude Alvarez, Pierre Moine, Benjamin Davido, Isabelle Etting, Djillali Annane, Islam Amine Larabi, Nicolas Simon |
| 49 |
[GO] |
2020―Oct―13 |
Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies |
Meng Zhao, Jieyu Lu, Yihu Tang, Yawei Dai, Jingxin Zhou, Yanhu Wu |
| 50 |
[GO] |
2020―Oct―04 |
Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19 |
Chia Siang Kow, Mamoon Aldeyab, Syed Shahzad Hasan |
| 51 |
[GO] |
2020―Sep―01 |
Iron chelation may harm patients with COVID-19 |
Michael D. Garrick, Andrew J. Ghio |
| 52 |
[GO] |
2020―Sep―01 |
Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19 |
Qibo Fu, Xiao Zheng, Yunlian Zhou, Lanfang Tang, Zhimin Chen, Shaoqing Ni |
| 53 |
[GO] |
2020―Sep―01 |
Reply: Iron chelation may harm patients with COVID-19 |
Anis Abobaker |
| 54 |
[GO] |
2020―Aug―11 |
Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials |
Can Chen, Kunming Pan, Bingjie Wu, Xiaoye Li, Zhangzhang Chen, Qing Xu, Xiaoyu Li, Qianzhou Lv |
| 55 |
[GO] |
2020―Jul―21 |
Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies |
Georgia Ragia, Vangelis G. Manolopoulos |
| 56 |
[GO] |
2020―Jun―30 |
Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome? |
Anis Abobaker |
| 57 |
[GO] |
2020―Jun―28 |
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 |
Francesco Ferrara, Giovanni Granata, Chiara Pelliccia, Raffaele La Porta, Antonio Vitiello |
| 58 |
[GO] |
2020―Jun―25 |
What about COVID-19 and arachidonic acid pathway? |
Malvina Hoxha |
| 59 |
[GO] |
2020―Jun―16 |
Calling for an exponential escalation scheme in vaccine development for COVID-19 |
Martin Wehling |
